A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

This study is testing rapcabtagene autoleucel — a CAR-T cell therapy — for people with two autoimmune diseases: rheumatoid arthritis (RA) and Sjogren's disease. CAR-T therapy (normally used in blood cancers) is being explored as a way to reset the immune system in severe autoimmune conditions that haven't responded to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed rheumatoid arthritis OR Sjogren's disease with active disease - You have failed standard treatments for your condition **You may NOT be eligible if...** - Your BMI is 17 or below, or 40 or above - You have a significant active or chronic infection - You have a history of cancer or lymphoma - You have had a prior bone marrow or organ transplant - You are pregnant, breastfeeding, or not using adequate contraception - You have inadequate organ function or a psychiatric condition preventing consent or compliance Talk to your doctor to see if this trial is right for you.